Aflibercept (2.0 mg)

Phase 3

63%

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

Oct 2026~

EYPT⭐Phase 3Phase 3

Aflibercept (2.0 mg) Phase 3 Results Expected

Aflibercept (2.0 mg) • Wet Age Related Macular Degeneration

Aug 2026~

EYPT⭐Phase 3Phase 3

Aflibercept (2.0 mg) Phase 3 Results Expected

Aflibercept (2.0 mg) • Wet Age Related Macular Degeneration

Drug Information

Target Indication

Wet Age Related Macular Degeneration